Biotech · Private company
Advenchen Laboratories, LLC
Track this companyFree. Adds Advenchen Laboratories, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- AL3818Phase 3 · Alveolar Soft Part SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- AL3818Phase 3 · Endometrial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Endometrial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DacarbazinePhase 3 · Alveolar Soft Part SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- Digoxin (0.25mg)Phase 3 · Alveolar Soft Part SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- Midazolam 2 mg for CYP3A4 phenotypingPhase 3 · Alveolar Soft Part SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Endometrial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Pegylated Liposomal Doxorubicin (PLD)Phase 3 · Endometrial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Rosuvastatin 10 mg tablet.Phase 3 · Alveolar Soft Part SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- TopotecanPhase 3 · Endometrial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AL3818Phase 2 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 17, 2019ClinicalTrials.gov NCT04165330 · fetched Nov 12, 2026
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)PHASE3 · RECRUITING · started Aug 15, 2017ClinicalTrials.gov NCT03016819 · fetched Nov 12, 2026
- Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)PHASE3 · UNKNOWN · started Dec 1, 2015ClinicalTrials.gov NCT02584478 · fetched Nov 12, 2026
- Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)PHASE1_PHASE2 · TERMINATED · started Nov 1, 2015ClinicalTrials.gov NCT02558348 · fetched Nov 12, 2026